Literature DB >> 8275429

Defining the invasive phenotype of proximal gastric cancer cells.

G K Schwartz1, H Wang, N Lampen, N Altorki, D Kelsen, A P Albino.   

Abstract

BACKGROUND: Adenocarcinoma of the proximal stomach is now the most rapidly rising cancer among men in the United States. The development of metastases is the major cause of morbidity and mortality for this aggressive disease. The mechanisms by which tumor cells invade the basement membrane are unknown for this disease. We have identified and established 5 invasive and noninvasive adenocarcinoma cell lines arising from the proximal stomach, which can be used to examine the mechanisms involved in tumor cell invasion.
METHODS: The expression of factors associated with tumor cell attachment, proteolysis, and inhibition of proteolysis was determined by reverse transcription of mRNA to cDNA and subsequent amplification by the polymerase chain reaction. In addition, cells were examined for morphologic changes by scanning electron microscopy.
RESULTS: Invasive proximal gastric cancer cells express the 72-kD form of collagenase type IV, whereas the noninvasive cells do not. Other factors examined (including the laminin receptor, cathepsin B, cathepsin L, urokinase-type plasminogen activator, and tissue inhibitor metalloproteinases) are expressed by both invasive and noninvasive gastric cancer cells, whereas collagenase type IV 92-kD form is not expressed by any of the cells examined. In addition, scanning electron microscopy revealed that all the invasive cell lines exhibit long cytoplasmic extensions. The noninvasive cells express short cytoplasmic projections and are rounder than the invasive proximal gastric cancer cell lines.
CONCLUSIONS: There are distinct phenotypic differences between invasive and noninvasive proximal gastric cancer cell lines both at the level of expression of mRNA for collagenase Type IV 72-kD and at the level of scanning electron microscopy with the expression of cytoplasmic projections. Clinical outcome may be associated with these phenotypic differences.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8275429     DOI: 10.1002/1097-0142(19940101)73:1<22::aid-cncr2820730106>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Study on the expression of matrix metallo proteinase-2 mRNA in human gastric cancer.

Authors:  Feng Ji; Wei-Lin Wang; Zi-Li Yang; You-Ming Li; Huai-Di Huang; Wei-Dong Chen
Journal:  World J Gastroenterol       Date:  1999-10       Impact factor: 5.742

2.  Changes of histology and expression of MMP-2 and nm23-H1 in primary and metastatic gastric cancer.

Authors:  Lin-Bo Wang; Zhi-Nong Jiang; Miao-Ying Fan; Chao-Yang Xu; Wen-Jun Chen; Jian-Guo Shen
Journal:  World J Gastroenterol       Date:  2008-03-14       Impact factor: 5.742

3.  A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens.

Authors:  M Nakamura; M Katano; K Fujimoto; T Morisaki
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

4.  Expression and role of matrix metalloproteinases MMP-2 and MMP-9 in human spinal column tumors.

Authors:  Z L Gokaslan; S K Chintala; J E York; V Boyapati; S Jasti; R Sawaya; G Fuller; D M Wildrick; G L Nicolson; J S Rao
Journal:  Clin Exp Metastasis       Date:  1998-11       Impact factor: 5.150

5.  Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Authors:  H Ito; Y Yonemura; H Fujita; K Tsuchihara; T Kawamura; N Nojima; T Fujimura; H Nose; Y Endo; T Sasaki
Journal:  Virchows Arch       Date:  1996-02       Impact factor: 4.064

6.  Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.

Authors:  Feng Ji; Yue-Liang Chen; En-Yun Jin; Wei-Lin Wang; Zi-Li Yang; You-Ming Li
Journal:  World J Gastroenterol       Date:  2005-06-07       Impact factor: 5.742

7.  Clinical value of extended biologic staging by bone marrow micrometastases and tumor-associated proteases in gastric cancer.

Authors:  M M Heiss; H Allgayer; K U Gruetzner; R Babic; K W Jauch; F W Schildberg
Journal:  Ann Surg       Date:  1997-12       Impact factor: 12.969

8.  Tumor-associated proteases and inhibitors in gastric cancer: analysis of prognostic impact and individual risk protease patterns.

Authors:  H Allgayer; R Babic; K U Grützner; B C Beyer; A Tarabichi; F W Schildberg; M M Heiss
Journal:  Clin Exp Metastasis       Date:  1998-01       Impact factor: 5.150

9.  Protein-bound polysaccharide PSK inhibits tumor invasiveness by down-regulation of TGF-beta1 and MMPs.

Authors:  H Zhang; T Morisaki; H Matsunaga; N Sato; A Uchiyama; K Hashizume; F Nagumo; J Tadano; M Katano
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

10.  Matrix metalloproteinases and their inhibitors in gastric cancer.

Authors:  G I Murray; M E Duncan; E Arbuckle; W T Melvin; J E Fothergill
Journal:  Gut       Date:  1998-12       Impact factor: 23.059

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.